Back

ANNEXA-4 - Andexanet alfa for reversal of Factor Xa inhibitors in patients with acute major bleeding

30 August 2016 (14:23 - 14:33)
Organised by:
Congress Presentation Part of: Hot Line preventive strategies 2 Medical treatment ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Stuart J Connolly

McMaster University, Hamilton (Canada)

11 More presentations in this session

Presentation thumbnail
ENSURE-AF study: Edoxaban for cardioversion of atrial fibrillation
Professor A. Goette (Paderborn, DE)
Slides Video
Presentation thumbnail
ENSURE-AF - Discussant review
Doctor R. Cappato (Sesto San Giovanni, IT)
Slides Video
Presentation thumbnail
ENSURE-AF - Panel discussion
Video
Presentation thumbnail
ANNEXA-4 - Discussant review
Professor G. Lip (Liverpool, GB)
Presentation thumbnail
ANNEXA-4 - Panel discussion
Video

Access the full session

Session thumbnail
Hot Line preventive strategies 2

The Event

Event poster

ESC Congress 2016

30 August 2016 14:23 CET
You may be interested in
thumbnail
Congress Presentation
Reversal agents to improve safety in patients treated with direct oral anticoagulants (DOACs).
26 August 2022
thumbnail
Congress Presentation
Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71
1 September 2025
thumbnail
Congress Presentation
Clinical outcomes after reversal of dabigatran in daily practice: real-world use of idarucizumab 2015-2019
28 August 2020
thumbnail
Congress Presentation
Factor XI inhibitors or direct oral anticoagulants in atrial fibrillation: an updated meta-analysis
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources